Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy

Margaret Showel, Robert A Brodsky, Hua Ling Tsai, Katlyn M. Briel, Jeanne Kowalski, Constance A. Griffin, Richard J Jones

Research output: Contribution to journalArticle

Abstract

Therapy-related myeloid neoplasms (t-MN) are well-recognized complications of high-dose cytotoxic therapy (HDT), such as autologous stem cell transplantation (ASCT). Clonal marrow cytogenetic abnormalities (CMCA) in the setting of normal bone marrow pathology have also been reported after HDT, but their significance remains unclear. We retrospectively evaluated occurrences of CMCA and t-MN in 785 patients treated with HDT at Johns Hopkins University between 1997 and 2007. Most patients received ASCT, but 106 patients who received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institutional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. Twenty-two patients developed t-MN, with an estimated cumulative incidence of 3.5% at 4 years. Eleven patients developed isolated CMCA, either transient or persistent without pathologic evidence of t-MN. Altogether, only 20 of the patients with reported CMCA subsequently developed t-MN during the follow-up period. Therefore, in the absence of pathologic evidence of t-MN, CMCA should not be considered diagnostic of t-MN.

Original languageEnglish (US)
Pages (from-to)1130-1138
Number of pages9
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume20
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Second Primary Neoplasms
Chromosome Aberrations
Bone Marrow
Stem Cell Transplantation
Therapeutics
Lymphoproliferative Disorders
Cyclophosphamide
Pathology
Incidence

Keywords

  • Chromosomal alterations in myeloid neoplasms
  • Clonal cytogenetic abnormalities
  • Treatment-related myeloid neoplasms

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy. / Showel, Margaret; Brodsky, Robert A; Tsai, Hua Ling; Briel, Katlyn M.; Kowalski, Jeanne; Griffin, Constance A.; Jones, Richard J.

In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Vol. 20, No. 8, 2014, p. 1130-1138.

Research output: Contribution to journalArticle

@article{c5d4c567d5bd418c955edc07785deed7,
title = "Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy",
abstract = "Therapy-related myeloid neoplasms (t-MN) are well-recognized complications of high-dose cytotoxic therapy (HDT), such as autologous stem cell transplantation (ASCT). Clonal marrow cytogenetic abnormalities (CMCA) in the setting of normal bone marrow pathology have also been reported after HDT, but their significance remains unclear. We retrospectively evaluated occurrences of CMCA and t-MN in 785 patients treated with HDT at Johns Hopkins University between 1997 and 2007. Most patients received ASCT, but 106 patients who received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institutional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. Twenty-two patients developed t-MN, with an estimated cumulative incidence of 3.5{\%} at 4 years. Eleven patients developed isolated CMCA, either transient or persistent without pathologic evidence of t-MN. Altogether, only 20 of the patients with reported CMCA subsequently developed t-MN during the follow-up period. Therefore, in the absence of pathologic evidence of t-MN, CMCA should not be considered diagnostic of t-MN.",
keywords = "Chromosomal alterations in myeloid neoplasms, Clonal cytogenetic abnormalities, Treatment-related myeloid neoplasms",
author = "Margaret Showel and Brodsky, {Robert A} and Tsai, {Hua Ling} and Briel, {Katlyn M.} and Jeanne Kowalski and Griffin, {Constance A.} and Jones, {Richard J}",
year = "2014",
doi = "10.1016/j.bbmt.2014.03.033",
language = "English (US)",
volume = "20",
pages = "1130--1138",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy

AU - Showel, Margaret

AU - Brodsky, Robert A

AU - Tsai, Hua Ling

AU - Briel, Katlyn M.

AU - Kowalski, Jeanne

AU - Griffin, Constance A.

AU - Jones, Richard J

PY - 2014

Y1 - 2014

N2 - Therapy-related myeloid neoplasms (t-MN) are well-recognized complications of high-dose cytotoxic therapy (HDT), such as autologous stem cell transplantation (ASCT). Clonal marrow cytogenetic abnormalities (CMCA) in the setting of normal bone marrow pathology have also been reported after HDT, but their significance remains unclear. We retrospectively evaluated occurrences of CMCA and t-MN in 785 patients treated with HDT at Johns Hopkins University between 1997 and 2007. Most patients received ASCT, but 106 patients who received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institutional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. Twenty-two patients developed t-MN, with an estimated cumulative incidence of 3.5% at 4 years. Eleven patients developed isolated CMCA, either transient or persistent without pathologic evidence of t-MN. Altogether, only 20 of the patients with reported CMCA subsequently developed t-MN during the follow-up period. Therefore, in the absence of pathologic evidence of t-MN, CMCA should not be considered diagnostic of t-MN.

AB - Therapy-related myeloid neoplasms (t-MN) are well-recognized complications of high-dose cytotoxic therapy (HDT), such as autologous stem cell transplantation (ASCT). Clonal marrow cytogenetic abnormalities (CMCA) in the setting of normal bone marrow pathology have also been reported after HDT, but their significance remains unclear. We retrospectively evaluated occurrences of CMCA and t-MN in 785 patients treated with HDT at Johns Hopkins University between 1997 and 2007. Most patients received ASCT, but 106 patients who received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institutional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. Twenty-two patients developed t-MN, with an estimated cumulative incidence of 3.5% at 4 years. Eleven patients developed isolated CMCA, either transient or persistent without pathologic evidence of t-MN. Altogether, only 20 of the patients with reported CMCA subsequently developed t-MN during the follow-up period. Therefore, in the absence of pathologic evidence of t-MN, CMCA should not be considered diagnostic of t-MN.

KW - Chromosomal alterations in myeloid neoplasms

KW - Clonal cytogenetic abnormalities

KW - Treatment-related myeloid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84904042361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904042361&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.03.033

DO - 10.1016/j.bbmt.2014.03.033

M3 - Article

VL - 20

SP - 1130

EP - 1138

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -